Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
| ▸ | CTSG | P08311 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6985389 | 0.78 | NOTUM (0.47) | NOTUMNSD2DRD2DRD3 | |
| SCHEMBL6989709 | 0.73 | NOTUM (0.50) | NOTUMNSD2ALOX5DRD2DRD3 | |
| SCHEMBL6985886 | 0.71 | NOTUM (0.60) | NOTUMNSD2ALOX5DRD2DRD3 | |
| SCHEMBL6989012 | 0.70 | NOTUM (0.46) | NOTUMNSD2DRD2DRD3CTSG | |
| SCHEMBL14632427 | 0.69 | NOTUM (0.57) | NOTUMALOX5DRD2DRD3HSD11B1 | |
| SCHEMBL6988378 | 0.69 | NOTUM (0.57) | NOTUMALOX5DRD2DRD3HSD11B1 | |
| SCHEMBL6984473 | 0.68 | NOTUM (0.53) | NOTUMNSD2KMT2AALOX5DRD2 | |
| SCHEMBL14632375 | 0.68 | NOTUM (0.56) | NOTUMKMT2AALOX5DRD2DRD3 | |
| SCHEMBL6987111 | 0.68 | NOTUM (0.50) | NOTUMNSD2ALOX5DRD2DRD3 | |
| SCHEMBL9105102 | 0.68 | NOTUM (0.53) | NOTUMNSD2KMT2AALOX5DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176465-A1 | Cyclic amino acid derivatives | MERCK PATENT GMBH (DE) | 2003-09-18 | — | — | US | disclosed |
| EP-1301506-A1 | CYCLIC AMINO ACID DERIVATIVES | MERCK PATENT GmbH (DE) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002006269-A1 | CYCLIC AMINO ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176465-A1 | Cyclic amino acid derivatives | F5, F11, F2 | NOTUM 4067/4885NSD2 4195/4885KMT2A 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.